{"product_id":"photalaz-1-talazoparib","title":"ハイイータン (Glumetinib)","description":"\u003ch2\u003eAbout Glumetinib or \u003cstrong\u003eGumarontinib\u003c\/strong\u003e\n\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eGlumetinib (SCC244) \u003c\/strong\u003ealso named \u003cstrong\u003eGumarontinib，\u003c\/strong\u003e is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor.Glumetinib has excellent pharmacokinetic characteristics with long half-life and high steady-state trough concentration in human body, which is conducive to the continuous inhibition of the target.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGlumetinib sold as brand name 海益坦® in china.\u003c\/li\u003e\n\u003cli\u003eGumarontinib sold as brand name ハイイータン® in Japan.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproval\u003c\/h2\u003e\u003cp\u003eIn June 2024, the MET inhibitor Glumetinib tablets were approved for marketing by the Ministry of Health, Labor and Welfare of Japan for the treatment of locally advanced or metastatic non-small cell lung cancer with MET exon 14 mutations.\u003c\/p\u003e\u003cp style=\"font-weight: 400\"\u003e\u003ca href=\"https:\/\/kk.haihepharma.com\/news\/news_2024062401.html\"\u003e《MET阻害剤「ハイイータン\u003csub\u003e® \u003c\/sub\u003e錠50 mg」\u003cem\u003eMET\u003c\/em\u003e遺伝子エクソン14スキッピング変異陽性の切除不能な進行・再発の非小細胞肺癌に対する製造販売承認を取得》\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.haihepharma.com\/en\/news\/details\/423\"\u003e《An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan》\u003c\/a\u003e\u003c\/p\u003e\u003ch2\u003eDosage and administration\u003c\/h2\u003e\u003cp\u003eThe recommended dose of Glumetinib is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.\u003cbr\u003eGlumetinib should be taken on an empty stomach. Take Glumetinib at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of Glumetinib and the next dose is more than 12 hours away, the patient should take Glumetinib.\u003c\/p\u003e\u003ch3\u003eDose adjustment\u003c\/h3\u003e\u003cp\u003eIf adverse events occur during the use of Glumetinib, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with Glumetinib can be stopped according to the specific situation. If a reduction in dose is required, the dose can be reduced to 40 mg, once a day.\u003c\/p\u003e","brand":"Haihe pharma, China","offers":[{"title":"Default Title","offer_id":44797946331179,"sku":"RL2720240718","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-0321.jpg?v=1787022071","url":"https:\/\/xomeds.com\/products\/photalaz-1-talazoparib","provider":"XOMEDS","version":"1.0","type":"link"}